.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Teva
Harvard Business School
Merck
Citi
Argus Health
Healthtrust
US Army
Daiichi Sankyo
Fuji
Cipla

Generated: September 24, 2017

DrugPatentWatch Database Preview

MOTOFEN Drug Profile

« Back to Dashboard

What is the patent landscape for Motofen, and when can generic versions of Motofen launch?

Motofen is a drug marketed by Sebela Ireland Ltd and is included in one NDA.

The generic ingredient in MOTOFEN is atropine sulfate; difenoxin hydrochloride. There are twenty-two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the atropine sulfate; difenoxin hydrochloride profile page.

Summary for Tradename: MOTOFEN

Patents:0
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Bulk Api Vendors: see list11
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:MOTOFEN at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sebela Ireland Ltd
MOTOFEN
atropine sulfate; difenoxin hydrochloride
TABLET;ORAL017744-002Approved Prior to Jan 1, 1982RXYesYes► Subscribe► Subscribe► Subscribe
Sebela Ireland Ltd
MOTOFEN HALF-STRENGTH
atropine sulfate; difenoxin hydrochloride
TABLET;ORAL017744-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: MOTOFEN

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Sebela Ireland Ltd
MOTOFEN
atropine sulfate; difenoxin hydrochloride
TABLET;ORAL017744-002Approved Prior to Jan 1, 1982► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Merck
Covington
Deloitte
UBS
Fish and Richardson
McKinsey
Federal Trade Commission
Cantor Fitzgerald
Accenture
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot